What is the address of KST Pharma?

The registered office of KST Pharma is located at Chaussée Brunehaut (Que) 142, 7972 Beloeil.

Is KST Pharma still active?

Yes. According to the CBE (29 October 2026) KST Pharma is active, legal situation “Normale toestand”, started on 4 February 2016.

Is KST Pharma registered on Peppol?

Yes, KST Pharma is registered on the Peppol network with ID 0208:0647823210.

What is the enterprise number of KST Pharma?

The enterprise number of KST Pharma is BE0647823210.

When was KST Pharma founded?

KST Pharma was founded on 4 February 2016.

Who are the directors of KST Pharma?

According to the 2025 annual accounts, the directors of KST Pharma are: KOEN STRAETMANS.

Is KST Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 4 February 2016; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did KST Pharma make in 2025?

KST Pharma posted a profit after taxes of € 140 in financial year 2025.

What is the revenue of KST Pharma?

As a small company, KST Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 115,734.

KST Pharma (Private Limited) - Beloeil - BE0647823210

Q: What does KST Pharma do?

KST Pharma is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 4 February 2016, 1 establishment.

Dossier KST Pharma, printed on 29 October 2026 from databakkes.be/en/0647823210/kst-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 32 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

KST Pharma from Beloeil, company number BE0647823210, closed financial year 2025 with a result of € 140 after tax. For that financial year KST Pharma recorded a gross margin of € 115,734 and equity of € 21,112. Compared with financial year 2024, the result moved from € 62,403 to € 140. The company is profitable. The buffer shrank hard: equity is 89 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 21, 2026.

What it is worth Shrank hard

€ 21,112

▼ 89% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 140

▼ € 62,263 vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 21,629

▼ 61% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 164,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Wage cost

€ 13,096

▲ 4% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 39,971

▼ 34% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 16,271

▼ 52% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 10,205

▲ 32% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 17,349

▲ 2% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 84,307 Gross margin 2022: € 84,307 First fiscal year in the series	€ 147,121 Gross margin 2023: € 147,121 ▲ 75% vs 2022 (€ 84,307) Favourable step	€ 134,211 Gross margin 2024: € 134,211 ▼ 9% vs 2023 (€ 147,121) Unfavourable step	€ 115,734 Gross margin 2025: € 115,734 ▼ 14% vs 2024 (€ 134,211) Unfavourable step	▼ 14%
Profit after taxes	€ 50,334 Profit after taxes 2022: € 50,334 First fiscal year in the series	€ 77,970 Profit after taxes 2023: € 77,970 ▲ 55% vs 2022 (€ 50,334) Favourable step	€ 62,403 Profit after taxes 2024: € 62,403 ▼ 20% vs 2023 (€ 77,970) Unfavourable step	€ 140 Profit after taxes 2025: € 140 ▼ € 62,263 vs 2024 (€ 62,403) Unfavourable step	▼ € 62,263
Equity	€ 105,399 Equity 2022: € 105,399 First fiscal year in the series	€ 182,569 Equity 2023: € 182,569 ▲ 73% vs 2022 (€ 105,399) Favourable step	€ 184,972 Equity 2024: € 184,972 ▲ 1% vs 2023 (€ 182,569) Favourable step	€ 21,112 Equity 2025: € 21,112 ▼ 89% vs 2024 (€ 184,972) Unfavourable step	▼ 89%
Total debts	€ 134,593 Total debts 2022: € 134,593 First fiscal year in the series	€ 114,644 Total debts 2023: € 114,644 ▼ 15% vs 2022 (€ 134,593) Favourable step	€ 58,708 Total debts 2024: € 58,708 ▼ 49% vs 2023 (€ 114,644) Favourable step	€ 147,395 Total debts 2025: € 147,395 ▲ 151% vs 2024 (€ 58,708) Unfavourable step	▲ 151%
Cash	€ 1,245 Cash 2022: € 1,245 First fiscal year in the series	€ 793 Cash 2023: € 793 ▼ 36% vs 2022 (€ 1,245) Unfavourable step	€ 55,188 Cash 2024: € 55,188 ▲ € 54,395 vs 2023 (€ 793) Favourable step	€ 21,629 Cash 2025: € 21,629 ▼ 61% vs 2024 (€ 55,188) Unfavourable step	▼ 61%
Retained profit	€ 86,799 Retained profit 2022: € 86,799 First fiscal year in the series	€ 163,969 Retained profit 2023: € 163,969 ▲ 89% vs 2022 (€ 86,799) Favourable step	€ 166,372 Retained profit 2024: € 166,372 ▲ 1% vs 2023 (€ 163,969) Favourable step	€ 2,512 Retained profit 2025: € 2,512 ▼ 98% vs 2024 (€ 166,372) Unfavourable step	▼ 98%
Dividend	€ 800 Dividend 2022: € 800 First fiscal year in the series	€ 800 Dividend 2023: € 800 Unchanged (€ 800) Unchanged	€ 60,000 Dividend 2024: € 60,000 ▲ € 59,200 vs 2023 (€ 800) Unchanged	€ 164,000 Dividend 2025: € 164,000 ▲ 173% vs 2024 (€ 60,000) Unchanged	▲ 173%
Bank debt	€ 69,521 Bank debt 2022: € 69,521 First fiscal year in the series	€ 51,771 Bank debt 2023: € 51,771 ▼ 26% vs 2022 (€ 69,521) Favourable step	€ 34,021 Bank debt 2024: € 34,021 ▼ 34% vs 2023 (€ 51,771) Favourable step	€ 16,271 Bank debt 2025: € 16,271 ▼ 52% vs 2024 (€ 34,021) Favourable step	▼ 52%
Balance sheet total	€ 239,992 Balance sheet total 2022: € 239,992 First fiscal year in the series	€ 297,214 Balance sheet total 2023: € 297,214 ▲ 24% vs 2022 (€ 239,992) Unchanged	€ 243,680 Balance sheet total 2024: € 243,680 ▼ 18% vs 2023 (€ 297,214) Unchanged	€ 168,506 Balance sheet total 2025: € 168,506 ▼ 31% vs 2024 (€ 243,680) Unchanged	▼ 31%

Key figures of KST Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to KST Pharma?

What happened at KST Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

May 21, 2026 New annual accounts for financial year 2025: profit of € 140 (▼ € 62,263 vs 2024). Source: NBB ↗
Feb 4, 2016 New establishment in Beloeil. KBO
2016 KOEN STRAETMANS became a director. NBB
Feb 4, 2016 Start of the company according to the CBE. KBO

In short

From € 50,334 profit in 2022 to € 140 profit in 2025.

Paid € 84,476 in corporate taxes since 2022.

Best year ever: 2023, with € 77,970 profit.

Paid out € 225,600 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

KOEN STRAETMANS

KST Pharma

FEBELCOFONDS

Behind KST Pharma is KOEN STRAETMANS. KOEN STRAETMANS is also behind FEBELCOFONDS.

Directors

According to the 2025 annual accounts

KOEN STRAETMANS

Director

Also active at: FEBELCOFONDS

since 2016

Establishments

Establishment units

Physical locations of this company

Registered office

Chaussée Brunehaut (Que) 142

7972 Beloeil

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Pharmacie Walcarius

€ 437,080 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0647.823.210

VAT number

BE 0647.823.210

Registered office

Chaussée Brunehaut (Que) 142, 7972 Beloeil

Names & denominations

KST Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

4 February 2016

Peppol

Active · Active since 3 Dec 2025

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

KST Pharma

Warning lights

Financials

What happened to KST Pharma?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions